SI1430057T1 - Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati - Google Patents

Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati

Info

Publication number
SI1430057T1
SI1430057T1 SI200230201T SI200230201T SI1430057T1 SI 1430057 T1 SI1430057 T1 SI 1430057T1 SI 200230201 T SI200230201 T SI 200230201T SI 200230201 T SI200230201 T SI 200230201T SI 1430057 T1 SI1430057 T1 SI 1430057T1
Authority
SI
Slovenia
Prior art keywords
pyrimidin
pyridinyl
tetrahydropyrimido
dihydroimidazo
derivatives
Prior art date
Application number
SI200230201T
Other languages
English (en)
Slovenian (sl)
Inventor
Thierry Gallet
Patrick Lardenois
Alistair Lochead
Severine Marguerie
Alain Nedelec
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01402432A external-priority patent/EP1295885A1/en
Priority claimed from EP02290489A external-priority patent/EP1340761A1/en
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Publication of SI1430057T1 publication Critical patent/SI1430057T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Agronomy & Crop Science (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
SI200230201T 2001-09-21 2002-09-19 Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati SI1430057T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01402432A EP1295885A1 (en) 2001-09-21 2001-09-21 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP02290489A EP1340761A1 (en) 2002-02-28 2002-02-28 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
PCT/EP2002/011128 WO2003027116A2 (en) 2001-09-21 2002-09-19 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives

Publications (1)

Publication Number Publication Date
SI1430057T1 true SI1430057T1 (sl) 2006-02-28

Family

ID=26077256

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230201T SI1430057T1 (sl) 2001-09-21 2002-09-19 Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati

Country Status (24)

Country Link
US (2) US7214682B2 (https=)
EP (2) EP1430057B1 (https=)
JP (3) JP4570362B2 (https=)
KR (1) KR100868841B1 (https=)
CN (2) CN100398541C (https=)
AR (1) AR036600A1 (https=)
AT (2) ATE401309T1 (https=)
AU (1) AU2002350487C1 (https=)
BR (1) BR0212896A (https=)
CA (1) CA2457965C (https=)
CY (1) CY1108341T1 (https=)
DE (2) DE60227718D1 (https=)
DK (2) DK1674456T3 (https=)
EA (1) EA006859B1 (https=)
ES (2) ES2247398T3 (https=)
HU (1) HUP0500328A3 (https=)
IL (2) IL160402A0 (https=)
MX (1) MXPA04002629A (https=)
NO (1) NO329565B1 (https=)
NZ (2) NZ531243A (https=)
PL (1) PL370349A1 (https=)
PT (1) PT1674456E (https=)
SI (1) SI1430057T1 (https=)
WO (1) WO2003027116A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457965C (en) * 2001-09-21 2010-06-01 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases
EP1454900A1 (en) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters
EP1557417B1 (en) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
WO2005070932A2 (en) 2004-01-22 2005-08-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101735211B (zh) * 2008-11-04 2012-11-14 复旦大学 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
CN102482286B (zh) * 2009-07-02 2015-07-15 赛诺菲 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途
HUE034503T2 (en) 2009-07-02 2018-02-28 Sanofi Sa 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
CN114957246B (zh) * 2021-02-19 2025-11-11 苏州恩华生物医药科技有限公司 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4（3H）-酮衍生物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
EP0948496A2 (en) * 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
JP2000264888A (ja) * 1999-01-11 2000-09-26 Sagami Chem Res Center 双環性ピリミジン誘導体、それらの製造中間体及びそれらの製造方法、並びにそれらを有効成分とする除草剤
BR0010652A (pt) * 1999-03-22 2002-07-16 Ortho Mcneil Pharm Inc Processo de preparação de ácido [s-(r*,s*)]-beta-[[[1-[1-oxo-3-(4-piperidinil)propil]-3-piperi dinil]carbonil]amino]-3-piridinapropanóico e derivados
WO2001042224A1 (en) * 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
CN100335479C (zh) * 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
AR030587A1 (es) * 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
CA2457965C (en) * 2001-09-21 2010-06-01 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives

Also Published As

Publication number Publication date
WO2003027116A3 (en) 2003-08-28
DE60205921D1 (de) 2005-10-06
DE60227718D1 (de) 2008-08-28
NO20041141L (no) 2004-06-21
CN1556809A (zh) 2004-12-22
NZ531243A (en) 2006-08-31
US7462621B2 (en) 2008-12-09
EP1430057A2 (en) 2004-06-23
JP4570362B2 (ja) 2010-10-27
HK1091208A1 (zh) 2007-01-12
IL160402A0 (en) 2004-07-25
US20050049261A1 (en) 2005-03-03
ATE401309T1 (de) 2008-08-15
ATE303388T1 (de) 2005-09-15
JP2010209089A (ja) 2010-09-24
DK1674456T3 (da) 2008-10-27
DK1430057T3 (da) 2006-01-16
CN1247585C (zh) 2006-03-29
BR0212896A (pt) 2004-10-13
DE60205921T2 (de) 2006-06-22
CA2457965A1 (en) 2003-04-03
EP1430057B1 (en) 2005-08-31
PL370349A1 (en) 2005-05-16
CN100398541C (zh) 2008-07-02
HUP0500328A3 (en) 2009-12-28
ES2247398T3 (es) 2006-03-01
AU2002350487B2 (en) 2008-01-31
NZ547205A (en) 2007-11-30
US7214682B2 (en) 2007-05-08
CN1817884A (zh) 2006-08-16
HUP0500328A2 (hu) 2005-07-28
EP1674456A2 (en) 2006-06-28
EP1674456B1 (en) 2008-07-16
JP2010159303A (ja) 2010-07-22
KR100868841B1 (ko) 2008-11-14
WO2003027116A2 (en) 2003-04-03
US20070167461A1 (en) 2007-07-19
IL160402A (en) 2008-08-07
NO329565B1 (no) 2010-11-15
AU2002350487C1 (en) 2008-10-02
EA006859B1 (ru) 2006-04-28
CY1108341T1 (el) 2014-02-12
AR036600A1 (es) 2004-09-22
CA2457965C (en) 2010-06-01
EA200400237A1 (ru) 2004-10-28
PT1674456E (pt) 2008-09-11
JP2005504810A (ja) 2005-02-17
MXPA04002629A (es) 2005-02-17
EP1674456A3 (en) 2006-07-05
ES2310787T3 (es) 2009-01-16
KR20040029486A (ko) 2004-04-06

Similar Documents

Publication Publication Date Title
SI1430057T1 (sl) Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati
SI1430056T1 (sl) Substituirani 2-pirimidinil-6,7,8,9-tetrahidropirimido (1,2-alfa)pirimidin-4-on in 7-pirimidinil-2,3-dihidroimidazo (1,2-alfa)pirimidin-5(1H)on derivati proti nevrodegenerativnim motnjam
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
AU7367001A (en) Pyrido(2,3-d)pyrimidine and pyrimido(4,5-d)pyrimidine nucleosides
AU1224902A (en) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
ATE251623T1 (de) Imidazo(1,2-a)pyridin- und pyrazolo(2,3- a)pyridinderivate
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
SI1480981T1 (sl) Derivati 1-(alkil), 1-(heteroaril)alkil- in 1-(aril)alkil)-7-(pirimidin-4-il)-imidazo(1,2-alfa)pirimidin-5(1H)-ona
SI1560830T1 (sl) Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov
AU2002215979A1 (en) Use of pyrazolo(4,3-D)pyrimidines
IL155379A0 (en) SUBSTITUTED 3,4-DIHYDRO-PYRIMIDO[1,2-a] PYRIMIDINES AND 3,4-DIHYDROPYRAZINO [1,2-a] PYRIMIDINES
SI1325010T1 (en) Substituted 3.4-dihydro-pyrimido (1,2-a)pyrimidines and 3.4-dihydropyrazino (1,2-a)pyrimidines
HK1054322A (en) Pyrido[2,3-d] pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
AU2002219350A1 (en) Pyrazolo(3,4-d)pyrimidine derivatives and their use as purinergic receptor antagonists
AU2002325550A1 (en) (1,2,4)triazolo(1,5-a)pyrimidine derivative
DK1325010T3 (da) Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner
HK1068632A (en) Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
HK1085201A (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
HK1084664A (en) Pyrazolo [1,5-a] pyrimidine derivatives
AU2002226519A1 (en) Pyrrolo(2,3-d)pyrimidine and their use as purinergic receptor antagonists
AU2002244935A1 (en) 8-thiazolyl(1,2,4)triazolo(1,5-c)pyrimidine derivative